N/A N=40 Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions
Depression
Primary: Bioequivalence Determined by Statistical Comparison Cmax — 11.5; 11.3 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Hepatitis, Chronic · Hepatitis C Virus
Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set — 6.11; -0.45 log10 IU/mL
Phase 2 N=38 CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Leukemia
Primary: Overall Response Rate (ORR) — 37 percentage of participants
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 3 N=4,363 Study of Quadrivalent Influenza Vaccine Among Children
Influenza
Primary: Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants…
Phase 4 N=252 Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)
Contraception
Primary: Number of Participants With Regular Menstrual Cycles — 192; 9; 3; 199 Participants
N/A N=62 A Prospective Study of Two Daily Disposable Contact Lenses
Myopia
Primary: Mean Change From Baseline in Subjective Contact Lens-related Dryness Symptoms at Week 4 as Assessed by the CLDEQ — -0.21; -0.17; -1.07; -0.92 Units on a scale
Phase 4 N=157 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0 — 0.40; 0.76; 2.00 Scores on a Scale
Phase 2 N=39 Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
Multiple Sclerosis · Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 45.5; 47.4 percentage of subjects
N/A N=32 Physiologic Adaptations to Interval and Continuous Running at Low Volume and Vigorous Intensity Over 14-Weeks.
Exhaustion - Physiological
Primary: Relative Maximal Oxygen Uptake — 47.8; 50.9; 49.7; 51.7 mL/(kg*min) — p=< 0.05
N/A N=2,248 Study to Evaluate the Prospective Payment System
Chronic Kidney Disease
Primary: Percentage of Participants Per Facility With Hemoglobin < 10 g/dL — 11.5; 11.0; 13.1; 12.0 percentage of participants per facility
Phase 4 N=353 A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia
Schizophrenia
Primary: Percentage of Responders as Per Clinical Global Impression - Improvement (CGI-I) Scale — 21.6 percentage of participants
Phase 2 N=4 Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
Autism
Primary: Extent of Absorption of Memantine (Part One) — 682.53 ng•h/mL
N/A N=10 Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
Atrial Fibrillation
Primary: Safety of Ablation Using the AFreeze Cryoablation System Consisting of the CoolLoop® Ablation Catheter, Its Steerable Sheath and the Cryoconsole Cryo-Caddy Assessed by…
Phase 2 N=10 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Brain and Central Nervous System Tumors
Primary: Number of Patients Surviving Without Disease Progression After 6 Months — 0 participants